<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02250937</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0431</org_study_id>
    <secondary_id>NCI-2014-02324</secondary_id>
    <secondary_id>2014-0431</secondary_id>
    <nct_id>NCT02250937</nct_id>
  </id_info>
  <brief_title>Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome</brief_title>
  <official_title>Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan,Cladribine, and Fludarabine Conditioning in Patients With AML and MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well venetoclax and sequential busulfan,&#xD;
      cladribine, and fludarabine phosphate before donor stem cell transplant work in treating&#xD;
      patients with acute myelogenous leukemia or myelodysplastic syndrome. Giving chemotherapy&#xD;
      before a donor peripheral blood stem cell transplant helps kill cancer cells in the body and&#xD;
      helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to&#xD;
      grow. When the healthy stem cells from a donor are infused into a patient, they may help the&#xD;
      patient's bone marrow make more healthy cells and platelets and may help destroy any&#xD;
      remaining cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare progression free survival of two schedules of venetoclax, timed sequential&#xD;
      busulfan, cladribine and fludarabine conditioning regimen in patients with acute myelogenous&#xD;
      leukemia (AML) and myelodysplastic syndrome (MDS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Compare overall survival between the two schedules. II. Compare non relapse mortality&#xD;
      between the two schedules. III. Compare neutrophil and platelet engraftment between the two&#xD;
      schedules. IV. Compare acute and chronic graft-versus-host disease (GVHD) between the two&#xD;
      schedules.&#xD;
&#xD;
      V. Compare cumulative incidence of relapse between the two schedules. VI. Compare grade&#xD;
      III/IV toxicity between the two schedules.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To study chemotherapy resistance. II. To study deoxyribonucleic acid (DNA) damage. III. To&#xD;
      study immune recovery and cytokines (both in plasma and cells). IV. To study BCL-2 family&#xD;
      expression, stem cell surface markers and intracellular signaling markers in AML cells at the&#xD;
      time of relapse.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      PREPARATIVE REGIMEN: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive venetoclax orally (PO) once daily (QD) on days -22 to -3 and busulfan&#xD;
      intravenously (IV) over 3 hours on days -13 and -12. Patients then receive fludarabine&#xD;
      phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6&#xD;
      to -3.&#xD;
&#xD;
      ARM II: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on&#xD;
      days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV&#xD;
      over 2 hours, and busulfan IV over 3 hours on days -6 to -3.&#xD;
&#xD;
      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) on day&#xD;
      0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2014</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At 6 months</time_frame>
    <description>The method of Kaplan and Meier will be used to estimate distribution of progression free survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Will test whether there is strong evidence that DFS differs between the two arms using a stratified log-rank test. Will use the Lan-DeMets alpha spending approach with an O'Brien-Fleming stopping boundary to compare the two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity of these regimens</measure>
    <time_frame>Up to 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of acute graft versus host disease (GVHD)</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Will use the method of Gooley et al to estimate the cumulative incidence of acute GVHD. Will use the method of Fine and Gary to fit regression models to the cumulative incidence outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GVHD</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Will use the method of Gooley et al to estimate the cumulative incidence of chronic GVHD. Will use the method of Fine and Gary to fit regression models to the cumulative incidence outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>The method of Kaplan and Meier will be used to estimate the distribution of overall survival. Cox proportional hazards regression analysis will be used to model the association between overall survival and covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>The method of Kaplan and Meier will be used to estimate time to neutrophil engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>The method of Kaplan and Meier will be used to estimate time to platelet engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Will use the method of Gooley et al to estimate the cumulative incidence of relapse. Will use the method of Fine and Gary to fit regression models to the cumulative incidence outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <description>Will use the method of Gooley et al to estimate the cumulative incidence of non-relapse mortality. Will use the method of Fine and Gary to fit regression models to the cumulative incidence outcomes. Logistic regression will be used to model the association between 100-day NRM and clinical and demographic covariates of interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -13 and -12. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.&#xD;
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PREPARATIVE REGIMEN: Patients receive venetoclax PO QD on days -22 to -3 and busulfan IV over 3 hours on days -20 and -13. Patients then receive fludarabine phosphate IV over 1 hour, cladribine IV over 2 hours, and busulfan IV over 3 hours on days -6 to -3.&#xD;
TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
    <other_name>Allogeneic</other_name>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
    <other_name>2-CdA</other_name>
    <other_name>2CDA</other_name>
    <other_name>CdA</other_name>
    <other_name>Cladribina</other_name>
    <other_name>Leustat</other_name>
    <other_name>Leustatin</other_name>
    <other_name>Leustatine</other_name>
    <other_name>RWJ-26251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSCT</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (busulfan days -13 and -12 before PBSCT)</arm_group_label>
    <arm_group_label>Arm II (busulfan days -20 and -13 before PBSCT)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biopsy-proven acute myeloid leukemia or myelodysplastic syndrome with&#xD;
             persistent disease or in remission&#xD;
&#xD;
          -  Human leukocyte antigen (HLA)-identical sibling or 8/8 matched unrelated donor&#xD;
             transplant&#xD;
&#xD;
          -  Patients age 18 to 70 years old; eligibility for pediatric patients will be determined&#xD;
             in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age&#xD;
             2-17 years may be enrolled after at least 10 adults (ages 18-70 years old) have been&#xD;
             assessed for safety at day 30&#xD;
&#xD;
          -  Direct bilirubin &lt; 1 mg/dl&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 ml/min (calculated creatinine clearance is permitted)&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) &gt;= 50% of expected corrected for&#xD;
             hemoglobin and/or volume&#xD;
&#xD;
          -  Forced vital capacity (FVC) &gt;= 50% of expected corrected for hemoglobin and/or volume&#xD;
&#xD;
          -  Diffusing capacity of the lungs for carbon monoxide (DLCO) &gt;= 50% of expected&#xD;
             corrected for hemoglobin and/or volume&#xD;
&#xD;
          -  Children unable to perform pulmonary function tests (e.g., less than 7 years old)&#xD;
             pulse oximetry of &gt;= 92% on room air&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 40%&#xD;
&#xD;
          -  Patient, legally authorized representative (LAR), or parent able to sign informed&#xD;
             consent; able to give assent for patients age 7-17&#xD;
&#xD;
          -  Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing&#xD;
             potential, defined as not post-menopausal for 12 months or no previous surgical&#xD;
             sterilization; women of child bearing potential must be willing to use an effective&#xD;
             contraceptive measure while on study&#xD;
&#xD;
          -  Performance score of &gt;= 70 by Karnofsky/Lansky or performance status (PS) 0 or 1&#xD;
             (Eastern Cooperative Oncology Group [ECOG] =&lt; 1)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior allogeneic or autologous transplantation&#xD;
&#xD;
          -  Uncontrolled infections&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) seropositivity&#xD;
&#xD;
          -  Hematopoietic cell transplantation (HCT) co-morbidity index score &gt; 3; the principal&#xD;
             investigator is the final arbiter of eligibility for comorbidity score &gt; 3&#xD;
&#xD;
          -  Patients with prior coronary artery disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uday R Popat</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uday Popat, MD</last_name>
    <phone>713-792-8750</phone>
    <email>upopat@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uday R. Popat</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Uday R. Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 24, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

